Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
Rong FanHatice SatilmisNiels VandewalleEmma VerheyePhilip VlummensAnke MaesCatharina MuylaertElke De BruyneEline MenuHolly EvansAndrew ChantryNathan De BeuleDirk HoseMarie TörngrenHelena ErikssonKarin VanderkerkenKen MaesKarine BreckpotKim De VeirmanPublished in: Journal for immunotherapy of cancer (2023)
Our study provides novel insights in the dual therapeutic effects of the immunomodulator tasquinimod and fosters its evaluation in combination therapy trials for MM patients.
Keyphrases
- combination therapy
- end stage renal disease
- multiple myeloma
- signaling pathway
- induced apoptosis
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- bone marrow
- cell cycle arrest
- dendritic cells
- acute myeloid leukemia
- bone mineral density
- immune response
- patient reported outcomes
- bone loss
- binding protein
- cell death
- pi k akt